News for Orexo AB (publ) (ORXOF)

Published at

Jan 10, 2025 3:00 PM

by gurufocus.com

positive

positive

Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

PR NewswireUPPSALA, Sweden, Jan. 10, 2025 OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. a

ORXOY ORXOF

Read more →
Published at

Oct 24, 2024 9:40 AM

by investing.com

negative

negative

Orexo Interim Report Q3 2024 By Investing.com

Orexo Interim Report Q3 2024

ORXOY ORXOF

Read more →
Published at

Oct 4, 2024 8:36 AM

by investing.com

positive

positive

Orexo ´s Nomination Committee for the Annual General Meeting 2025 By Investing.com

Orexo ´s Nomination Committee for the Annual General Meeting 2025

ORXOY ORXOF

Read more →
Published at

Jul 10, 2024 8:40 AM

by investing.com

positive

positive

Orexo AB ´s sustainability work ranked among top 5% by EcoVadis By Investing.com

Orexo AB ´s sustainability work ranked among top 5% by EcoVadis

ORXOY ORXOF

Read more →
Published at

May 8, 2024 8:36 AM

by investing.com

negative

negative

Orexo Q1 2024 Interim Report By Investing.com

Orexo Q1 2024 Interim Report

ORXOY ORXOF

Read more →
Published at

Apr 17, 2024 8:28 AM

by investing.com

positive

positive

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US By Investing.com

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

ORXOY ORXOF

Read more →
Published at

Mar 28, 2024 8:24 AM

by investing.com

positive

positive

Orexo publishes the Annual and Sustainability Report for 2023 By Investing.com

Orexo publishes the Annual and Sustainability Report for 2023

ORXOY ORXOF

Read more →
Published at

Feb 8, 2024 8:25 AM

by marketscreener.com

negative

negative

Orexo Interim Report Q4 2023, incl. Full Year Report

UPPSALA, Sweden, Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m EBITDA of SEK 12.4 m , EBITDA excluding...

ORXOY ORXOF

Read more →
Published at

Nov 2, 2023 8:22 AM

by marketscreener.com

mixed

mixed

Orexo Q3 2023 Interim Report

Big step forward in launching OX124 in the US UPPSALA, Sweden, Nov. 2, 2023 /PRNewswire/ -- Q3 2023 highlights› Total net revenues of SEK 156.1 m › EBITDA of SEK -9.5 m , EBITDA...

SUNPHARMA-BL.NS ORXOY ORXOF

Read more →
Published at

Oct 26, 2023 5:11 PM

by marketscreener.com

positive

positive

Orexo´s Nomination Committee for the Annual General Meeting 2024

UPPSALA, Sweden, Oct. 26, 2023 /PRNewswire/ -- Prior to the Annual General Meeting in 2024, that will take place on April 26, a Nomination Committee has been appointed. The shareholders having...

ORXOY ORXOF

Read more →